Condensed Combined and Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Dec. 31, 2019 |
Dec. 31, 2018 |
Dec. 31, 2019 |
Dec. 31, 2018 |
|
Research and Development Expense [Member] | ||||
Share-based compensation expense | $ 311 | $ 198 | $ 2,683 | $ 997 |
Research and Development Expense [Member] | Roivant Sciences Ltd. (RSL) [Member] | ||||
Costs allocated from related party | 0 | 475 | 152 | 3,209 |
General and Administrative Expense [Member] | ||||
Share-based compensation expense | 1,103 | 39 | 2,440 | 78 |
General and Administrative Expense [Member] | Roivant Sciences Ltd. (RSL) [Member] | ||||
Costs allocated from related party | $ 487 | $ 637 | $ 1,001 | $ 930 |
X | ||||||||||
- Definition Costs of sales and operating expenses for the period incurred from transactions with related parties. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of expense for employee benefit and equity-based compensation. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|